Versorgung von Patienten mit neovaskul?rer altersabh?ngiger Makuladegeneration in Deutschland

详细信息    查看全文

• 作者：PD Dr. R.P. Finger (1) (2)
  F.G. Holz (1)
  
• 关键词：Therapie ; Vaskul?rer endothelialer Wachstumsfaktorhemmer ; Ranibizumab ; Optische Koh?renztomographie ; Sehverlust ; Treatment ; Vascular endothelial growth factor inhibition ; Ranibizumab ; Optical coherence tomography ; Loss of vision
• 刊名：Der Ophthalmologe
• 出版年：2014
• 出版时间：May 2014
• 年：2014
• 卷：111
• 期：5
• 页码：438-442
• 全文大小：
• 参考文献：1. Abraham P, Yue H, Wilson L (2010) Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 2. Am J Ophthalmol 150:315-24 CrossRef
  2. Bartels SJ, Horn S, Sharkey P et al (1997) Treatment of depression in older primary care patients in health maintenance organizations. Int J Psychiatry Med 27:215-31 CrossRef
  3. Bertram B, Gante C, Hilgers RD (2013) Zunahme der Untersuchungen wegen Katarakt, Glaukom, diabetischer Retinopathie und Makuladegeneration: Vergleichende Querschnittstudie der Jahre 2010 und 1997 in Augenarztpraxen. Ophthalmologe. doi: 10.1007/s00347-013-2966-z
  4. Catt Research Group, Martin DF, Maguire MG et al (2011) Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 364:1897-908 CrossRef
  5. Ehlken C, Mueller S, Bauer-Steinhusen U et al (2013) Intravitreale operative Medikamentengabe bei nAMD-Patienten in Deutschland: die PONS-Studie. Jahreskongress der Deutschen Ophthalmologischen Gesellschaft 2013, Berlin
  6. Finger RP, Fimmers R, Holz FG et al (2011) Prevalence and causes of registered blindness in the largest federal state of Germany. Br J Ophthalmol 95:1061-067 CrossRef
  7. Finger RP, Fleckenstein M, Scholl HP et al (2007) Therapeutic anti-VEGF in ophthalmology: physiopathology and treatment of age-related macular degeneration. Pharm Unserer Zeit 36:424-30 CrossRef
  8. Finger RP, Holz FG (2012) Versorgung von ?lteren Menschen mit neovaskularer altersabh?ngiger Makuladegeneration. Ophthalmologe 109:474-78 CrossRef
  9. Finger RP, Wiedemann P, Blumhagen F et al (2013) Treatment patterns, visual acuity and quality-of-life outcomes of the WAVE study -a noninterventional study of ranibizumab treatment for neovascular age-related macular degeneration in Germany. Acta Ophthalmol 91:540-46 CrossRef
  10. Fung AE, Lalwani GA, Rosenfeld PJ et al (2007) An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 143:566-83 CrossRef
  11. Heimes B, Gunnemann F, Wilhelm A et al (2013) Langzeitverlauf und Compliance unter Anti-VEGF-Therapie bei exsudativer AMD im klinischen Alltag. Jahreskongress der Deutschen Ophthalmologischen Gesellschaft 2013, Berlin
  12. Holz FG, Aura Steering Committee (2013) Retrospective analysis of the real-world utilization of anti-VEGF therapy in neovascular AMD in Germany. Jahreskongress der Deutschen Ophthalmologischen Gesellschaft 2013, Berlin
  13. Ivan Study Investigators, Chakravarthy U, Harding SP et al (2012) Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology 119:1399-411 CrossRef
  14. Koeberlein J, Beifuss C, Schaffert C et al (2013) The economic burden of visual impairment and blindness -a systematic review. BMJ Open. doi:10.1136/bmjopen-2013-003471
  15. Kruger Falk M, Kemp H, Sorensen TL (2013) Four-year treatment results of neovascular age-related macular degeneration with ranibizumab and causes for discontinuation of treatment. Am J Ophthalmol 155:89-5 CrossRef
  16. Kumar A, Sahni JN, Stangos AN et al (2011) Effectiveness of ranibizumab for neovascular age-related macular degeneration using clinician-determined retreatment strategy. Br J Ophthalmol 95:530-33 CrossRef
  17. Lalwani GA, Rosenfeld PJ, Fung AE et al (2009) A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol 148:43-8 CrossRef
  18. Mitchell P, Korobelnik JF, Lanzetta P et al (2010) Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials. Br J Ophthalmol 94:2-3 CrossRef
  19. Oubraham H, Cohen SY, Samimi S et al (2011) Inject and extend dosing versus dosing as needed: a comparative retrospective study of ranibizumab in exudative age-related macular degeneration. Retina 31:26-0 CrossRef
  20. Pauleikhoff D, Bertram B, Holz FG et al (2013) Anti-VEGF therapy of neovascular age-related macular degeneration: therapeutic strategies status december 2012. Klin Monatsbl Augenheilkd 230:170-77 CrossRef
  21. Porz G, Scholl HP, Holz FG et al (2010) Methods for estimating personal costs of disease using retinal diseases as an example. Ophthalmologe 107:216-20, 222 CrossRef
  22. Regillo CD, Brown DM, Abraham P et al (2008) Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol 145:239-48 CrossRef
  23. Rothenbuehler SP, Waeber D, Brinkmann CK et al (2009) Effects of ranibizumab in patients with subfoveal choroidal neovascularization attributable to age-related macular degeneration. Am J Ophthalmol 147:831-37 CrossRef
  24. Shienbaum G, Gupta OP, Fecarotta C et al (2012) Bevacizumab for neovascular age-related macular degeneration using a treat-and-extend regimen: clinical and economic impact. Am J Ophthalmol 153:468-73 CrossRef
  25. Spaide R (2007) Ranibizumab according to need: a treatment for age-related macular degeneration. Am J Ophthalmol 143:679-80 CrossRef
  26. Wedding U, Hoffken K, Friedrich C et al (2007) Health services research and geriatrics: deficits and research approaches using the example of colorectal carcinoma and anaemia. Z Arztl Fortbild Qualitatssich 101:587-92
  27. Wickremasinghe SS, Xie J, Lim J et al (2011) Variants in the APOE gene are associated with improved outcome after anti-VEGF treatment for neovascular AMD. Invest Ophthalmol Vis Sci 52:4072-079 CrossRef
  28. Ziemssen F, Wiedon A, Spital G et al (2013) Ocean -Beobachtung von Therapieans?tzen mit Lucentis im Praxisalltag. Jahreskongress der Deutschen Ophthalmologischen Gesellschaft 2013, Berlin
  
• 作者单位：PD Dr. R.P. Finger (1) (2)
  F.G. Holz (1)
  
  1. Universit?ts-Augenklinik Bonn, Ernst-Abbe-Str. 2, 53127, Bonn, Deutschland
  2. Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, University of Melbourne, Melbourne, Australien
  
• ISSN：1433-0423

文摘

In neovascular age-related macular degeneration (NVAMD) successful treatment outcome depends on regular intravitreal injections of vascular endothelial growth factor inhibitors (anti-VEGF). Several observational trials on the use of ranibizumab in the clinical routine demonstrated a low injection frequency, a low number of ophthalmic reviews which included optical coherence tomography, and suboptimal treatment outcomes in Germany. To date it remains unclear whether the use of ranibizumab reflects the use of all anti-VEGF agents including aflibercept and bevacizumab in the clinical routine in Germany. However, based on available data, treatment provision and outcomes seem to be suboptimal, in particular for elderly patients with NVAMD. As poorly treated NVAMD carries a high risk of loss of vision and ultimately blindness, service provision and treatment outcomes need to be improved.